Is SOD1 loss of function involved in amyotrophic lateral sclerosis?

Brain

Volumn 136, Issue 8, 2013, Pages 2342-2358

  Saccon, Rachele A ^a   Bunton Stasyshyn, Rosie K A ^a   Fisher, Elizabeth M C ^a   Fratta, Pietro ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Loss of function; Motor neuron disease; Superoxide dismutase 1

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMIC ACID; MUTANT PROTEIN; RNA;

ALZHEIMER DISEASE; AMNESIA; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN ISCHEMIA; DNA METHYLATION; ENZYME ACTIVITY; GENE SEQUENCE; HUMAN; KNOCKOUT MOUSE; MOTOR SYSTEM; MUSCLE DISEASE; NERVOUS SYSTEM; NEUROMUSCULAR SYNAPSE; NEUROPATHY; NEUROPHYSIOLOGY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; REVIEW;

EID: 84880956773     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt097     Document Type: Review

References (163)

1. Acevedo-Arozena A, Kalmar B, Essa S, Ricketts T, Joyce P, Kent R, et al. A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Dis Model Mech 2011; 4: 686-700.
2. Acsadi G, Lee I, Li X, Khaidakov M, Pecinova A, Parker GC, et al. Mitochondrial dysfunction in a neural cell model of spinal muscular atrophy. J Neurosci Res 2009; 87: 2748-56.
3. Andersen PM, Al Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011; 7: 603-15.
4. Andersen PM, Nilsson P, Ala-Hurula V, Keranen ML, Tarvainen I, Haltia T, et al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet 1995; 10: 61-6.
5. Andrus PK, Fleck TJ, Gurney ME, Hall ED. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1998; 71: 2041-8.
6. Apostolski S, Nikolic J, Bugarski-Prokopljevic C, Miletic V, Pavlovic S, Filipovic S. Serum and CSF immunological findings in ALS. Acta Neurol Scand 1991; 83: 96-8.
7. Baloh RH, Rakowicz W, Gardner R, Pestronk A. Frequent atrophic groups with mixed-type myofibers is distinctive to motor neuron syndromes. Muscle Nerve 2007a; 36: 107-10.
8. Baloh RH, Schmidt RE, Pestronk A, Milbrandt J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci 2007b; 27: 422-30.
9. Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 2010; 48: 629-41.
10. Beal MF. Role of excitotoxicity in human neurological disease. Curr Opin Neurobiol 1992; 2: 657-62.
11. Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993; 364: 584.
12. Bhusari SS, Dobosy JR, Fu V, Almassi N, Oberley T, Jarrard DF. Superoxide dismutase 1 knockdown induces oxidative stress and DNA methylation loss in the prostate. Epigenetics 2010; 5: 402-9.
13. Birve A, Neuwirth C, Weber M, Marklund SL, Nilsson AC, Jonsson PA, et al. A novel SOD1 splice site mutation associated with familial ALS revealed by SOD activity analysis. Hum Mol Genet 2010; 19: 4201-6.
14. Bodendorf U, Danner S, Fischer F, Stefani M, Sturchler-Pierrat C, Wiederhold KH, et al. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem 2002; 80: 799-806.
15. Borchelt DR, Lee MK, Slunt HS, Guarnieri M, Xu ZS, Wong PC, et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci USA 1994; 91: 8292-6.
16. Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010; 13: 1396-403.
17. Boukaftane Y, Khoris J, Moulard B, Salachas F, Meininger V, Malafosse A, et al. Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. Can J Neurol Sci 1998; 25: 192-6.
18. Bowling AC, Schulz JB, Brown RH Jr., Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993; 61: 2322-5.
19. Broom WJ, Greenway M, Sadri-Vakili G, Russ C, Auwarter KE, Glajch KE, et al. 50bp deletion in the promoter for superoxide dismutase 1 (SOD1) reduces SOD1 expression in vitro and may correlate with increased age of onset of sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008; 9: 229-37.
20. Browne SE, Bowling AC, Baik MJ, Gurney M, Brown RH Jr., Beal MF. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J Neurochem 1998; 71: 281-7.
21. Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327-38.
22. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, et al. Aggregation and motor neuron toxicity of an ALSlinked SOD1 mutant independent from wild-type SOD1. Science 1998; 281: 1851-4.
23. Casaril M, Corso F, Bassi A, Capra F, Gabrielli GB, Stanzial AM, et al. Decreased activity of scavenger enzymes in human hepatocellular carcinoma, but not in liver metastases. International Journal of Clinical and Laboratory research 1994; 24: 94-97.
24. Cassereau J, Chevrollier A, Gueguen N, Desquiret V, Verny C, Nicolas G, et al. Mitochondrial dysfunction and pathophysiology of Charcot-Marie-Tooth disease involving GDAP1 mutations. Exp Neurol 2011; 227: 31-41.
25. Chang LY, Slot JW, Geuze HJ, Crapo JD. Molecular immunocytochemistry of the CuZn superoxide dismutase in rat hepatocytes. J Cell Biol 1988; 107: 2169-79.
26. Chestnut BA, Chang Q, Price A, Lesuisse C, Wong M, Martin LJ. Epigenetic regulation of motor neuron cell death through DNA methylation. J Neurosci 2011; 31: 16619-36.
27. Chia R, Tattum MH, Jones S, Collinge J, Fisher EM, Jackson GS. Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis. PLoS One 2010; 5: e10627.
28. Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L. Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 2005; 280: 11648-55.
29. Crapo JD, Oury T, Rabouille C, Slot JW, Chang LY. Copper, zinc superoxide dismutase is primarily a cytosolic protein in human cells. Proc Natl Acad Sci USA 1992; 89: 10405-9.
30. Crespo-Barreto J, Fryer JD, Shaw CA, Orr HT, Zoghbi HY. Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genet 2010; 6: e1001021.
31. Culotta VC, Klomp LW, Strain J, Casareno RL, Krems B, Gitlin JD. The copper chaperone for superoxide dismutase. J Biol Chem 1997; 272: 23469-72.
32. Culotta VC, Lin SJ, Schmidt P, Klomp LW, Casareno RL, Gitlin J. Intracellular pathways of copper trafficking in yeast and humans. Adv Exp Med Biol 1999; 448: 247-54.
33. de Lustig ES, Serra JA, Kohan S, Canziani GA, Famulari AL, Dominguez RO. Copper-zinc superoxide dismutase activity in red blood cells and serum in demented patients and in aging. J Neurol Sci 1993; 115: 18-25.
34. De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau KF, et al. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet 2007; 16: 2720-8.
35. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 1993; 261: 1047-51.
36. Deng HX, Shi Y, Furukawa Y, Zhai H, Fu R, Liu E, et al. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci USA 2006; 103: 7142-7.
37. Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, et al. FUSimmunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol 2010; 67: 739-48.
38. Dengler R, Konstanzer A, Kuther G, Hesse S, Wolf W, Struppler A. Amyotrophic lateral sclerosis: macro-EMG and twitch forces of single motor units. Muscle Nerve 1990; 13: 545-50.
39. Didion SP, Kinzenbaw DA, Schrader LI, Faraci FM. Heterozygous CuZn superoxide dismutase deficiency produces a vascular phenotype with aging. Hypertension 2006; 48: 1072-9.
40. Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson RL, Van Remmen H, et al. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 2005; 24: 367-380.
41. Ezzi SA, Urushitani M, Julien JP. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem 2007; 102: 170-8.
42. Faes L, Callewaert G. Mitochondrial dysfunction in familial amyotrophic lateral sclerosis. J Bioenerg Biomembr 2011; 43: 587-92.
43. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 2004; 185: 232-40.
44. Fischer LR, Glass JD. Oxidative stress induced by loss of Cu, Znsuperoxide dismutase (SOD1) or superoxide-generating herbicides causes axonal degeneration in mouse DRG cultures. Acta Neuropathol 2010; 119: 249-59.
45. Fischer LR, Igoudjil A, Magrané J, Li Y, Hansen JM, Manfredi G, et al. SOD1 targeted to the mitochondrial intermembrane space prevents motor neuropathy in the Sod1 knockout mouse. Brain 2011; 134: 196-209.
46. Fischer LR, Li Y, Asress SA, Jones DP, Glass JD. Absence of SOD1 leads to oxidative stress in peripheral nerve and causes a progressive distal motor axonopathy. Exp Neurol 2012; 233: 163-71.
47. Fitzmaurice PS, Shaw IC, Kleiner HE, Miller RT, Monks TJ, Lau SS, et al. Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve 1996; 19: 797-8.
48. Flood DG, Reaume AG, Gruner JA, Hoffman EK, Hirsch JD, Lin YG, et al. Hindlimb motor neurons require Cu/Zn superoxide dismutase for maintenance of neuromuscular junctions. Am J Pathol 1999; 155: 663-72.
49. Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, et al. Novel antibodies reveal inclusions containing nonnative SOD1 in sporadic ALS patients. PLoS One 2010; 5: e11552.
50. Fratta P. Antisense makes sense for ALS. Lancet Neurol 2013; 12: 416-417.
51. Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci 2000; 20: 2534-42.
52. Fridovich I. Biological effects of the superoxide radical. Arch Biochem Biophys 1986; 247: 1-11.
53. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem 1995; 64: 97-112.
54. Fukada K, Nagano S, Satoh M, Tohyama C, Nakanishi T, Shimizu A, et al. Stabilization of mutant Cu/Zn superoxide dismutase (SOD1) protein by coexpressed wild SOD1 protein accelerates the disease progression in familial amyotrophic lateral sclerosis mice. Eur J Neurosci 2001; 14: 2032-6.
55. Ge WW, Leystra-Lantz C, Sanelli TR, McLean J, Wen W, Strong W, et al. Neuronal tissue-specific ribonucleoprotein complex formation on SOD1 mRNA: alterations by ALS SOD1 mutations. Neurobiol Dis 2006; 23: 342-50.
56. Graffmo KS, Forsberg K, Bergh J, Birve A, Zetterstrom P, Andersen P, et al. Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Human Mol Genet 2013; 22: 51-60.
57. Guareschi S, Cova E, Cereda C, Ceroni M, Donetti E, Bosco DA, et al. An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci USA 2012; 109: 5074-9.
58. Guo W, Chen Y, Zhou X, Kar A, Ray P, Chen X, et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat Struct Mol Biol 2011; 18: 822-30.
59. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264: 1772-5.
60. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707-19.
61. Hayward C, Brock DJH, Minns RA, Swingler RJ. Homozygosity for Asn86Ser mutation in the CuZn superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. J Med Genet 1998; 35: 174.
62. Ho YS, Gargano M, Cao J, Bronson RT, Heimler I, Hutz RJ. Reduced fertility in female mice lacking copper-zinc superoxide dismutase. J Biol Chem 1998; 273: 7765-9.
63. Hu J, Chen K, Ni B, Li L, Chen G, Shi S. A novel SOD1 mutation in amyotrophic lateral sclerosis with a distinct clinical phenotype. Amyotroph Lateral Scler 2012; 13: 149-54.
64. Huang TT, Yasunami M, Carlson EJ, Gillespie AM, Reaume AG, Hoffman EK, et al. Superoxide-mediated cytotoxicity in superoxide dismutase-deficient fetal fibroblasts. Arch Biochem Biophys 1997; 344: 424-32.
65. Huppke P, Brendel C, Korenke GC, Marquardt I, Donsante A, Yi L, et al. Molecular and biochemical characterization of a unique mutation in CCS, the human copper chaperone to superoxide dismutase. Hum Mutat 2012; 33: 1207-15.
66. Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009; 187: 761-72.
67. Jaarsma D, Haasdijk ED, Grashorn JA, Hawkins R, van Duijn W, Verspaget HW, et al. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol Dis 2000; 7: 623-43.
68. Jang YC, Lustgarten MS, Liu Y, Muller FL, Bhattacharya A, Liang H, et al. Increased superoxide in vivo accelerates age-associated muscle atrophy through mitochondrial dysfunction and neuromuscular junction degeneration. FASEB J 2010; 24: 1376-90.
69. Jonsson PA, Bergemalm D, Andersen PM, Gredal O, Brannstrom T, Marklund SL. Inclusions of amyotrophic lateral sclerosis-linked superoxide dismutase in ventral horns, liver, and kidney. Ann Neurol 2008; 63: 671-5.
70. Jonsson PA, Ernhill K, Andersen PM, Bergemalm D, Brannstrom T, Gredal O, et al. Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. Brain 2004; 127: 73-88.
71. Joyce PI, Fratta P, Fisher EM, Acevedo-Arozena A. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome 2011; 22: 420-48.
72. Kato M, Aoki M, Ohta M, Nagai M, Ishizaki F, Nakamura S, et al. Marked reduction of the Cu/Zn superoxide dismutase polypeptide in a case of familial amyotrophic lateral sclerosis with the homozygous mutation. Neurosci Lett 2001; 312: 165-8.
73. Keithley EM, Canto C, Zheng QY, Wang X, Fischel-Ghodsian N, Johnson KR. Cu/Zn superoxide dismutase and age-related hearing loss. Hear Res 2005; 209: 76-85.
74. Keller GA, Warner TG, Steimer KS, Hallewell RA. Cu, Zn superoxide dismutase is a peroxisomal enzyme in human fibroblasts and hepatoma cells. Proc Natl Acad Sci USA 1991; 88: 7381-5.
75. Kennel PF, Finiels F, Revah F, Mallet J. Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: an electromyographic study. Neuroreport 1996; 7: 1427-31.
76. Khare SD, Caplow M, Dokholyan NV. The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2004; 101: 15094-9.
77. Kobayashi J, Kuroda M, Kawata A, Mochizuki Y, Mizutani T, Komori T, et al. Novel G37V mutation of SOD1 gene in autopsied patient with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012; 13: 570-72.
78. Kondo T, Reaume AG, Huang TT, Carlson E, Murakami K, Chen SF, et al. Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J Neurosci 1997; 17: 4180-9.
79. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012; 74: 1031-44.
80. Kostrominova TY. Advanced age-related denervation and fiber-type grouping in skeletal muscle of SOD1 knockout mice. Free Radic Biol Med 2010; 49: 1582-93.
81. Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell 2009; 136: 1001-4.
82. Larkin LM, Davis CS, Sims-Robinson C, Kostrominova TY, Remmen HV, Richardson A, et al. Skeletal muscle weakness due to deficiency of CuZnsuperoxide dismutase is associated with loss of functional innervation. Am J Physiol Regul Integr Comp Physiol 2011; 301: R1400-7.
83. Leonardi A, Abbruzzese G, Arata L, Cocito L, Vische M. Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J Neurol 1984; 231: 75-8.
84. Liaw KY, Lee PH, Wu FC, Tsai JS, Lin-Shiau SY. Zinc, copper, and superoxide dismutase in hepatocellular carcinoma. Am J Gastroenterol 1997; 92: 2260-2263.
85. Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE, et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008; 452: 713-8.
86. Lin MT, Wang MY, Liaw KY, Lee PH, Chien SF, Tsai JS, et al. Superoxide dismutase in hepatocellular carcinoma affects patient prognosis. Hepatogastroenterology 2001; 48: 1102-1105.
87. Lobsiger CS, Boillee S, McAlonis-Downes M, Khan AM, Feltri ML, Yamanaka K, et al. Schwann cells expressing dismutase active mutant SOD1 unexpectedly slow disease progression in ALS mice. Proc Natl Acad Sci USA 2009; 106: 4465-70.
88. Lu XH, Yang XW. "Huntingtin Holiday": Progress toward an antisense therapy for Huntington's disease. Neuron 2012; 74: 964-6.
89. Maekawa S, Leigh PN, King A, Jones E, Steele JC, Bodi I, et al. TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations. Neuropathology 2009; 29: 672-83.
90. Marikovsky M, Ziv V, Nevo N, Harris-Cerruti C, Mahler O. Cu/Zn superoxide dismutase plays important role in immune response. J Immunol 2003; 170: 2993-3001.
91. Marklund SL, Holme E, Hellner L. Superoxide dismutase in extracellular fluids. Clin Chim Acta 1982; 126: 41-51.
92. Matsuoka T, Fujii N, Kondo A, Iwaki A, Hokonohara T, Honda H, et al. An autopsied case of sporadic adult-onset amyotrophic lateral sclerosis with FUS-positive basophilic inclusions. Neuropathology 2011; 31: 71-6.
93. Matzuk MM, Dionne L, Guo Q, Kumar TR, Lebovitz RM. Ovarian function in superoxide dismutase 1 and 2 knockout mice. Endocrinology 1998; 139: 4008-11.
94. Miller T, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. A Phase I, randomised, first-in-human study of an antisense oligonucleotide directed against SOD1 delivered intrathecally in SOD1-familial ALS patients. Lancet Neurol 2013; 12: 435-442.
95. Mitchell JJ, Trakadis YJ, Scriver CR. Phenylalanine hydroxylase deficiency. Genet Med 2011; 13: 697-707.
96. Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler 2008; 9: 177-83.
97. Muller FL, Liu Y, Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem 2004; 279: 49064-73.
98. Muller FL, Song W, Liu Y, Chaudhuri A, Pieke-Dahl S, Strong R, et al. Absence of CuZn superoxide dismutase leads to elevated oxidative stress and acceleration of age-dependent skeletal muscle atrophy. Free Radic Biol Med 2006; 40: 1993-2004.
99. Munch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci USA 2011; 108: 3548-53.
100. Murray LM, Talbot K, Gillingwater TH. Review: neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy. Neuropathol Appl Neurobiol 2010; 36: 133-56.
101. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006; 7: 710-23.
102. Pokrishevsky E, Grad LI, Yousefi M, Wang J, Mackenzie IR, Cashman NR. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS One 2012; 7: e35050.
103. Pramatarova A, Figlewicz DA, Krizus A, Han FY, Ceballos-Picot I, Nicole A, et al. Identification of new mutations in the Cu/Zn superoxide dismutase gene of patients with familial amyotrophic lateral sclerosis. Am J Genet 1995; 56: 592-6.
104. Proescher JB, Son M, Elliott JL, Culotta VC. Biological effects of CCS in the absence of SOD1 enzyme activation: implications for disease in a mouse model for ALS. Hum Mol Genet 2008; 17: 1728-37.
105. Prudencio M, Durazo A, Whitelegge JP, Borchelt DR. An examination of wild-type SOD1 in modulating the toxicity and aggregation of ALS-associated mutant SOD1. Hum Mol Genet 2010; 19: 4774-89.
106. Pun S, Santos AF, Saxena S, Xu L, Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 2006; 9: 408-19.
107. Pupillo E, Messina P, Logroscino G, Zoccolella S, Chio A, Calvo A, et al. Trauma and amyotrophic lateral sclerosis: a case-control study from a population-based registry. Eur J Neurol 2012; 19: 1509-17.
108. Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, Chakrabartty A. Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem 2004; 279: 15499-504.
109. Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005; 11: 429-33.
110. Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005; 11: 423-8.
111. Ratovitski T, Corson LB, Strain J, Wong P, Cleveland DW, Culotta VC, et al. Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Hum Mol Genet 1999; 8: 1451-60.
112. Ravits J, Laurie P, Fan Y, Moore DH. Implications of ALS focality: rostralcaudal distribution of lower motor neuron loss postmortem. Neurology 2007; 68: 1576-82.
113. Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996; 13: 43-7.
114. Reddi AR, Culotta VC. SOD1 integrates signals from oxygen and glucose to repress respiration. Cell 2013; 152: 224-35.
115. Robberecht W, Sapp P, Viaene MK, Rosen D, McKenna-Yasek D, Haines J, et al. Cu/Zn superoxide dismutase activity in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1994; 62: 384-7.
116. Roe JA, Butler A, Scholler DM, Valentine JS, Marky L, Breslauer KJ. Differential scanning calorimetry of Cu, Zn-superoxide dismutase, the apoprotein, and its zinc-substituted derivatives. Biochemistry 1988; 27: 950-8.
117. Rosen DR, Bowling AC, Patterson D, Usdin TB, Sapp P, Mezey E, et al. A frequent ala 4 to val superoxide dismutase-1 mutation is associated with a rapidly progressive familial amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3: 981-7.
118. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
119. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009; 65 (Suppl 1): S3-9.
120. Saito Y, Yokota T, Mitani T, Ito K, Anzai M, Miyagishi M, et al. Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model. J Biol Chem 2005; 280: 42826-30.
121. Sasaki S, Aoki M, Nagai M, Kobayashi M, Itoyama Y. Mitochondrial alterations in transgenic mice with an H46R mutant Cu/Zn superoxide dismutase gene. J Neuropathol Exp Neurol 2009; 68: 365-73.
122. Sato T, Nakanishi T, Yamamoto Y, Andersen PM, Ogawa Y, Fukada K, et al. Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology 2005; 65: 1954-7.
123. Schwartz PJ, Reaume A, Scott R, Coyle JT. Effects of over-and underexpression of Cu, Zn-superoxide dismutase on the toxicity of glutamate analogs in transgenic mouse striatum. Brain Res 1998; 789: 32-39.
124. Shaw PJ, Ince PG, Falkous G, Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 1995; 38: 691-5.
125. Shefner JM, Reaume AG, Flood DG, Scott RW, Kowall NW, Ferrante RJ, et al. Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy. Neurology 1999; 53: 1239-46.
126. Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, et al. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 2001; 917: 97-104.
127. Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 2004; 62: 1758-65.
128. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 1991; 88: 10540-3.
129. Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006; 116: 2290-6.
130. Smith RG, Henry YK, Mattson MP, Appel SH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 1998; 44: 696-9.
131. Somwar R, Erdjument-Bromage H, Larsson E, Shum D, Lockwood WW, Yang G, et al. Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci USA 2011; 108: 16375-80.
132. Son M, Fu Q, Puttaparthi K, Matthews CM, Elliott JL. Redox susceptibility of SOD1 mutants is associated with the differential response to CCS over-expression in vivo. Neurobiol Dis 2009; 34: 155-62.
133. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319: 1668-72.
134. Stadtman ER. Protein oxidation and aging. Science 1992; 257: 1220-4.
135. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. Chem Res Toxicol 1997; 10: 485-94.
136. Sturtz LA, Diekert K, Jensen LT, Lill R, Culotta VC. A fraction of yeast Cu, Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria. A physiological role for SOD1 in guarding against mitochondrial oxidative damage. J Biol Chem 2001; 276: 38084-9.
137. Subramaniam JR, Lyons WE, Liu J, Bartnikas TB, Rothstein J, Price DL, et al. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat Neurosci 2002; 5: 301-7.
138. Synofzik M, Ronchi D, Keskin I, Basak AN, Wilhelm C, Gobbi C, et al. Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS. Hum Mol Genet 2012; 21: 3568-74.
139. Takahashi M, Dinse GE, Foley JF, Hardisty JF, Maronpot RR. Comparative prevalence, multiplicity, and progression of spontaneous and vinyl carbamate-induced liver lesions in five strains of male mice. Toxicol Pathology 2002; 30: 599-605.
140. Towne C, Setola V, Schneider BL, Aebischer P. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. Mol Ther 2011; 19: 274-83.
141. Turner BJ, Ackerley S, Davies KE, Talbot K. Dismutase-competent SOD1 mutant accumulation in myelinating Schwann cells is not detrimental to normal or transgenic ALS model mice. Hum Mol Genet 2010; 19: 815-24.
142. Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008; 85: 94-134.
143. Wang J, Xu G, Borchelt DR. Mapping superoxide dismutase 1 domains of non-native interaction: roles of intra-and intermolecular disulfide bonding in aggregation. J Neurochem 2006; 96: 1277-88.
144. Wang L, Deng HX, Grisotti G, Zhai H, Siddique T, Roos RP. Wild-type SOD1 overexpression accelerates disease onset of a G85R SOD1 mouse. Hum Mol Genet 2009a; 18: 1642-51.
145. Wang L, Grisotti G, Roos RP. Mutant SOD1 knockdown in all cell types ameliorates disease in G85R SOD1 mice with a limited additional effect over knockdown restricted to motor neurons. J Neurochem 2010; 113: 166-74.
146. Wang L, Gutmann DH, Roos RP. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum Mol Genet 2011; 20: 286-93.
147. Wang L, Pytel P, Feltri ML, Wrabetz L, Roos RP. Selective knockdown of mutant SOD1 in Schwann cells ameliorates disease in G85R mutant SOD1 transgenic mice. Neurobiol Dis 2012; 48: 52-7.
148. Wang L, Sharma K, Grisotti G, Roos RP. The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis. Neurobiol Dis 2009b; 35: 234-0.
149. Wang X, Culotta VC, Klee CB. Superoxide dismutase protects calcineurin from inactivation. Nature 1996; 383: 434-7.
150. Watanabe Y, Kuno N, Kono Y, Nanba E, Ohama E, Nakashima K, et al. Absence of the mutant SOD1 in familial amyotrophic lateral sclerosis (FALS) with two base pair deletion in the SOD1 gene. Acta Neurol Scand 1997; 95: 167-72.
151. Wei JP, Srinivasan C, Han H, Valentine JS, Gralla EB. Evidence for a novel role of copper-zinc superoxide dismutase in zinc metabolism. J Biol Chem 2001; 276: 44798-803.
152. Wen HL, Lin YT, Ting CH, Lin-Chao S, Li H, Hsieh-Li HM. Stathmin, a microtubule-destabilizing protein, is dysregulated in spinal muscular atrophy. Hum Mol Genet 2010; 19: 1766-78.
153. Weydert CJ, Cullen JJ. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protoc 2010; 5: 51-66.
154. Wilcox KC, Zhou L, Jordon JK, Huang Y, Yu Y, Redler RL, et al. Modifications of superoxide dismutase (SOD1) in human erythrocytes: a possible role in amyotrophic lateral sclerosis. J Biol Chem 2009; 284: 13940-7.
155. Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain-and loss-of-function in neurodegenerative diseases. EMBO J 2008; 27: 336-49.
156. Wong PC, Waggoner D, Subramaniam JR, Tessarollo L, Bartnikas TB, Culotta VC, et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc Natl Acad Sci USA 2000; 97: 2886-91.
157. Wright PD, Wightman N, Huang M, Weiss A, Sapp PC, Cuny GD, et al. A high-throughput screen to identify inhibitors of SOD1 transcription. Front Biosci (Elite Ed) 2012; 4: 2801-8.
158. Yip PK, Malaspina A. Spinal cord trauma and the molecular point of no return. Mol Neurodegener 2012; 7: 6.
159. Yoon EJ, Park HJ, Kim GY, Cho HM, Choi JH, Park HY, et al. Intracellular amyloid beta interacts with SOD1 and impairs the enzymatic activity of SOD1: implications for the pathogenesis of amyotrophic lateral sclerosis. Exp Mol Med 2009; 41: 611-7.
160. Yoshida T, Maulik N, Engelman RM, Ho YS, Das DK. Targeted disruption of the mouse Sod I gene makes the hearts vulnerable to ischemic reperfusion injury. Circ Res 2000; 86: 264-9.
161. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 2002; 33: 337-49.
162. Zinman L, Liu HN, Sato C, Wakutani Y, Marvelle AF, Moreno D, et al. A mechanism for low penetrance in an ALS family with a novel SOD1 deletion. Neurology 2009; 72: 1153-9.
163. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90: 905-81.